Artelo's Q2 Loss, Going Concern Warning, and ATM Sales Update

summarizeSummary

Artelo Biosciences posted a $2.4 million Q2 net loss and reiterated going concern doubts. With $4.2 million in cash, the company continues to raise capital through its ATM, selling 386,668 shares after quarter-end for $354,000.

check_boxKey Events · Earnings and Guidance · ARTL

• Q2 Net Loss of $2.4M

  The second quarter of 2026 brought a net loss of $2.4 million, an improvement from the $3.2 million loss in the same period last year. For the first six months, the net loss totaled $5.4 million.

• Going Concern Warning Reiterated

  Management again expressed substantial doubt about the company's ability to continue as a going concern, citing only $4.2 million in cash as of June 30, 2026.

• ATM Sales Continue Post-Quarter

  After June 30, 2026, the company issued 386,668 shares under its ATM Sales Agreement, generating net proceeds of $354,000.

• Authorized Shares Increased to 500M

  On July 17, 2026, shareholders approved an increase in authorized common stock from 166,666,667 to 500,000,000 shares, enabling further dilution.

auto_awesomeAnalysis · ARTL · Life Sciences

A net loss of $2.4 million for Q2 2026 pushed Artelo Biosciences' six-month deficit to $5.4 million. The company again flagged substantial doubt about its ability to continue as a going concern, with cash of just $4.2 million as of June 30, 2026. After the quarter ended, 386,668 shares were sold under the ATM for net proceeds of $354,000, and shareholders approved a 3x increase in authorized shares to 500 million, paving the way for further dilution. The stock trades near its 52-week low at $0.74, underscoring severe financial distress.